Potential roles of AMP-activated protein kinase in liver regeneration in mice with acute liver injury
- Authors:
- Published online on: January 30, 2018 https://doi.org/10.3892/mmr.2018.8522
- Pages: 5390-5395
Abstract
Introduction
Acute liver injury induced by drugs, poisons or infections is a common health problem worldwide, which remains one of the leading causes of death (1). To alleviate the liver damage and improve the outcomes, extensive studies have been conducted to investigate the mechanisms underlying the development of liver injury (2–5). Importantly, the liver has strong regenerative activity after injury to compensate liver cell loss (6–8). The regeneration process is crucial for the recovery of hepatic structure and function (9–12).
AMP-activated protein kinase (AMPK) is a serine/threonine kinase. It is usually regarded as a sensor of cellular energy status used to keep up a delicate balance by monitoring both the short- and long-term total body energy requirements (13). Interestingly, recent studies have found that AMPK was extensively involved in various energy-intensive physiological and pathophysiological processes, such as inflammation (14), autophagy (15–17) and proliferation (18–21). Therefore, AMPK is rapidly emerging as a novel target for pathophysiological and pharmacological research (22).
There is increasing evidence that AMPK is involved in the development of hepatic disorders. Several studies have found that AMPK plays crucial roles in the development of cholestatic liver diseases, nonalcoholic fatty liver disease and liver fibrosis (23–25). In addition, AMPK also have potential value for the pharmacological intervention of liver injury induced by carbon tetrachloride (CCl4), endotoxin or ischemia (26–28). Although the crucial roles of AMPK in liver injury have been reported, the pathological significance of AMPK in the regeneration stage post acute liver injury was unclear.
Because liver regeneration includes a serial of highly active molecular responses, which requires intensive energy supply (9), we then suspected that AMPK might regulate the procedure of liver regeneration. In the present study, the potential role of AMPK in liver regeneration was investigated in mice with CCl4-induced toxic liver injury (13). In this widely used animal model, the phosphorylation status of AMPK post CCl4 exposure was detected. Then, the activity of AMPK was inhibited by a selective AMPK inhibitor, compound C (29,30), and the degree of liver regeneration was determined.
Materials and methods
Experimental animals
The male KM mice (Mus musculus Km) weighing 18–22 g were purchased from the Experimental Animal Center of Chongqing Medical University (Chongqing, China). Mice were kept in a 12-h light/dark cycle with ad libitum water and food. All experimental protocols involving the animals were approved by the Institutional Animal Care and Use Committee of Chongqing Medical University.
Reagents
CCl4 was obtained from Chengdu Kelong Chemical Reagent Factory (Chengdu, China). The AMPK inhibitor F6-[4-[2-(1-piperidinyl)ethoxy]phenyl]-3- (4-pyridinyl)-pyrazolo[1,5-a]pyrimidine (compound C) was purchased from Cayman Chemical (Ann Arbor, Michigan, MI, USA). The alanine aminotransferase (ALT) detection kit was purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). Rabbit anti-mouse antibodies against AMPK, phosphorylated AMPK (p-AMPK, Thr172) and β-actin were purchased from Cell signaling Technology (Danvers, MA, USA). Rabbit anti-mouse antibody against proliferating cell nuclear antigen (PCNA) antibody was purchased from Abcam (Cambridge, UK). The BCA protein assay kit, the horseradish peroxidase-conjugated goat anti-rabbit antibody and the enhanced chemiluminescence (ECL) reagents were obtained from Pierce Biotechnology (Rockford, IL, USA).
Experimental design
To induce acute liver injury, the mice received intraperitoneal injection of CCl4 (1%, dissolved in olive oil, 0.8 ml/kg). To determine the phosphorylation status of hepatic AMPK, the mice were anesthetized and sacrificed at various timepoints post CCl4 exposure (0, 24 and 48 h; n=8 for each group), the liver and plasma samples were harvested for further experiments. To investigate the potential roles of AMPK in acute liver injury, the mice were randomly divided into 4 groups (n=8 for each group): i) the control (CON) group, mice received vehicle only; ii) the compound C group, mice received the AMPK inhibitor compound C (15 mg/kg, i.p.) only; iii) the CCl4 group, mice exposed to CCl4; iv) the CCl4 + compound C group, mice received compound C 0.5 h prior to CCl4 challenge. The animals were sacrificed 24 h post CCl4 exposure, the liver and plasma samples were harvested. To investigate the potential roles of AMPK in liver injury, the mice were randomly divided into 4 groups (n=8 for each group): i) the CON group, mice received vehicle only; ii) the compound C group, mice received the AMPK inhibitor compound C (15 mg/kg, i.p.) only; iii) the CCl4 group, mice exposed to CCl4; iv) the CCl4 + compound C group, mice received compound C 24 h post CCl4 challenge. The animals were sacrificed 48 h post CCl4 exposure, the liver and plasma samples were harvested. The plasma samples were collected in the heparin tubes and were then centrifuged at 5,000 RPM for 15 min at 4°C. The supernatants were collected for further examinations.
Determination of liver enzymes
The plasma samples were collected with the method described above. The levels of ALT in plasma samples were determined following the manufacturer's instructions. The enzymatic activities were calculated according to the standard curve.
Histochemistry
The liver samples were fixed in formalin, embedded in paraffin, and the liver sections were evaluated with hematoxylin and eosin staining under light microscope (Olympus Corp., Tokyo, Japan).
Immunoblot analysis
The proteins were extracted from the liver samples and the concentration of the protein samples was determined by BCA protein assay kit (Pierce Biotechnology). Protein extracts were separated on 10 or 8% SDS-PAGE gels, then transferred to nitrocellulose membrane (Millipore, Billerica, MA, USA). After incubation with the 5% (w/v) skimmed milk in Tris-buffered saline (TBST) containing 0.1% Tween-20 for 2 h at room temperature, the membranes were incubated with primary antibodies overnight at 4°C. And then, the membranes were washed by TBST (containing 0.05% Tween-20), then incubated with secondary antibody for 1.5 h at 37°C and then washed by TBST. Antibody binding was visualized with an ECL chemiluminescence system (Pierce Biotechnology).
Statistical analysis
Data were presented as mean ± SD and analyzed by one-way ANOVA with Turkey's post hoc test in SPSS13.0. P<0.05 was considered to indicate a statistically significant difference.
Results
AMPK was activated post CCl4 challenge
The immunoblot analysis showed that CCl4 exposure did not stimulate the phosphorylation of AMPK 24 h post-CCl4 administration, but the phosphorylation level of AMPK was upregulated 48 h post-CCl4 exposure (Fig. 1). The upregulation of p-AMPK 48 h post-CCl4 exposure was accompanied with increased expression of PCNA and recovery of ALT level (Figs. 2 and 3).
Pre-insult treatment with an AMPK inhibitor had no obvious effects on liver injury
To determine the potential roles of AMPK on CCl4-induced liver injury, the AMPK inhibitor compound C was administered before CCl4 exposure. The experimental data shown that pretreatment with compound C had no significant effects on CCl4-induced elevation of ALT in plasma (Fig. 4). Consistently, the histopathological examination found no obvious difference in CCl4-challenged mice with or without compound C administration (Fig. 5).
Delayed inhibition of AMPK suppressed liver regeneration
To investigate whether AMPK is involved in liver regeneration post CCl4 challenge, compound C was administered 24 h post CCl4 exposure. The experimental data shown that post-treatment with compound C significantly suppressed AMPK phosphorylation 48 h post CCl4 exposure (Fig. 6). Post-treatment with compound C also suppressed CCl4-induced expression of PCNA 48 h post CCl4 exposure (Fig. 7). Meanwhile, the recovery of ALT level 48 h post CCl4 exposure was impaired by compound C administered post CCl4 exposure (Fig. 8).
Discussion
AMPK has been regarded as a crucial metabolic regulator which plays central roles in the maintenance of energy homeostasis (22). Our previous studies have found that AMPK provided anti-inflammatory benefits in mice with acute hepatitis induced by carbon tetrachloride or endotoxin (26,31). Several studies have found that AMPK was involved in the regulation of cellular proliferation (32–34). In the present study, we found that pharmacological inhibition of AMPK suppressed liver regeneration post CCl4-induced acute liver injury. Consistently, similar results have been obtained in a regenerative model with partial hepatectomy (11,18,35). These data suggests that AMPK might have positive roles in liver regeneration.
CCl4 is a representative hepatotoxin which induces severe liver injury quickly, the degree of liver damage usually peaks at 24 h after CCl4 exposure, followed by liver regeneration and recovery (13). In the present study, the immunoblot analysis indicated that the phosphorylation level of AMPK significantly increased 48 h post CCl4 challenge. In another model with endotoxin-induced acute liver injury, we also found that endogenous AMPK was mainly phosphorylated at the late stage (36). In the present study, pretreatment with the AMPK inhibitor compound C had little effects on the elevation of ALT in plasma and the degree of histological abnormalities in liver. Therefore, endogenous AMPK mainly functions at the regeneration stage in CCl4-exposed mice.
Because the phosphorylation of AMPK was associated with the expression of PCNA, a well-documented molecular marker of cellular proliferation (37), we also determined the roles of AMPK at the regeneration stage by treatment with the AMPK inhibitor 24 h post CCl4 exposure. The results indicated that post-insult inhibition of AMPK significantly suppressed the expression PCNA, which was accompanied with delayed decline of ALT. These data suggests that CCl4-induced activation of AMPK might act as a positive regulator in liver regeneration.
There is a considerable amount of researches have demonstrated a crucial link between AMPK and cellular proliferation (18–20). A study in cardiac fibroblasts found that AMPK suppressed cell cycle progression via modulating the expression of p21 and p27 (38). In addition, the suppressive effects of AMPK on tumor cell proliferation have been observed in neuroblastoma cells, breast cancer cells, prostate cancer cells and cervical cancer cells (39). These data suggests that activation of AMPK might prevent proliferation under some circumstance.
On the contrary, it was reported that treatment with the AMPK inhibitor compound C induced cell cycle arrest and suppressed the growth of colorectal cancer cells (40,41). The stimulatory actions of AMPK on proliferation were also confirmed by molecular approaches in prostate cancer cells and glioma cells (20,42). In addition, the in vivo promotive activities of AMPK on regeneration were observed in mice with mitochondrial myopathy or partial hepatectomy (19,21). Therefore, AMPK might have positive or negative effects on cellular proliferation in different pathological conditions.
Taken together, the present study found that endogenous AMPK was mainly activated at the regeneration stage in mice with CCl4-induced acute liver injury and it might function as a positive regulator in liver regeneration. Although the molecular mechanisms underlying the stimulatory activities of AMPK on liver regeneration remain to be further investigated, the present study suggests that AMPK might play crucial roles in the recovery of liver structure and function after severe liver damage.
Acknowledgements
The present study was supported by the grants from the Shandong Provincial Natural Science Foundation (ZR2015HL126) and the Training Program of Chongqing Medical University (no. 201419).
References
Hotchkiss RS and Nicholson DW: Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol. 6:813–822. 2006. View Article : Google Scholar : PubMed/NCBI | |
Ikeda T: Idiosyncratic drug hepatotoxicity: Strategy for prevention and proposed mechanism. Curr Med Chem. 22:528–537. 2015. View Article : Google Scholar : PubMed/NCBI | |
Yan J and Li S and Li S: The role of the liver in sepsis. Int Rev Immunol. 33:498–510. 2014. View Article : Google Scholar : PubMed/NCBI | |
Gómez-Lechón MJ, Lahoz A, Gombau L, Castell JV and Donato MT: In vitro evaluation of potential hepatotoxicity induced by drugs. Curr Pharm Des. 16:1963–1977. 2010. View Article : Google Scholar : PubMed/NCBI | |
Li X, Akhtar S, Kovacs EJ, Gamelli RL and Choudhry MA: Inflammatory response in multiple organs in a mouse model of acute alcohol intoxication and burn injury. J Burn Care Res. 32:489–497. 2011. View Article : Google Scholar : PubMed/NCBI | |
Fausto N, Campbell JS and Riehle KJ: Liver regeneration. Hepatology. 43 2 Suppl 1:S45–S53. 2006. View Article : Google Scholar : PubMed/NCBI | |
Fausto N and Campbell JS: The role of hepatocytes and oval cells in liver regeneration and repopulation. Mech Dev. 120:117–130. 2003. View Article : Google Scholar : PubMed/NCBI | |
Michalopoulos GK and DeFrances MC: Liver regeneration. Science. 276:60–66. 1997. View Article : Google Scholar : PubMed/NCBI | |
Hardie DG, Ross FA and Hawley SA: AMPK: A nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 13:251–262. 2012. View Article : Google Scholar : PubMed/NCBI | |
Yamamoto T, Kojima T, Murata M, Takano K, Go M, Hatakeyama N, Chiba H and Sawada N: p38 MAP-kinase regulates function of gap and tight junctions during regeneration of rat hepatocytes. J Hepatol. 42:707–718. 2005. View Article : Google Scholar : PubMed/NCBI | |
Yan XP, Wang S, Yang Y and Qiu YD: Effects of n-3 polyunsaturated fatty acids on rat livers after partial hepatectomy via LKB1-AMPK signaling pathway. Transplant Proc. 43:pp. 3604–3612. 2011; View Article : Google Scholar : PubMed/NCBI | |
Li G and G LG: Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration. Acta Pharm Sin B. 5:93–98. 2015. View Article : Google Scholar : PubMed/NCBI | |
Li SQ, Zhu S, Wan XD, Xu ZS and Ma Z: Neutralization of ADAM8 ameliorates liver injury and accelerates liver repair in carbon tetrachloride-induced acute liver injury. J Toxicol Sci. 39:339–351. 2014. View Article : Google Scholar : PubMed/NCBI | |
Sun H, Zhu X, Lin W, Zhou Y, Cai W and Qiu L: Interactions of TLR4 and PPARγ, dependent on AMPK signalling pathway contribute to anti-inflammatory effects of vaccariae hypaphorine in endothelial cells. Cell Physiol Biochem. 42:1227–1239. 2017. View Article : Google Scholar : PubMed/NCBI | |
Zhang L, Fang Y, Cheng X, Lian Y, Xu H, Zeng Z and Zhu H: TRPML1 participates in the progression of alzheimer's disease by regulating the PPARγ/AMPK/Mtor signalling pathway. Cell Physiol Biochem. 43:2446–2456. 2017. View Article : Google Scholar : PubMed/NCBI | |
Yang F, Zhang L, Gao Z, Sun X, Yu M, Dong S, Wu J, Zhao Y, Xu C, Zhang W and Lu F: Exogenous H2S protects against diabetic cardiomyopathy by activating autophagy via the AMPK/mTOR pathway. Cell Physiol Biochem. 43:1168–1187. 2017. View Article : Google Scholar : PubMed/NCBI | |
Kemp BE, Mitchelhill KI, Stapleton D, Michell BJ, Chen ZP and Witters LA: Dealing with energy demand: The AMP-activated protein kinase. Trends Biochem Sci. 24:22–25. 1999. View Article : Google Scholar : PubMed/NCBI | |
Varela-Rey M, Beraza N, Lu SC, Mato JM and Martinez-Chantar ML: Role of AMP-activated protein kinase in the control of hepatocyte priming and proliferation during liver regeneration. Exp Biol Med (Maywood). 236:402–408. 2011. View Article : Google Scholar : PubMed/NCBI | |
Merlen G, Gentric G, Celton-Morizur S, Foretz M, Guidotti JE, Fauveau V, Leclerc J, Viollet B and Desdouets C: AMPKα1 controls hepatocyte proliferation independently of energy balance by regulating Cyclin A2 expression. J Hepatol. 60:152–159. 2014. View Article : Google Scholar : PubMed/NCBI | |
Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, Hyduke DR, Collins BT, Gagnon G, Kallakury B, et al: AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther. 8:733–741. 2009. View Article : Google Scholar : PubMed/NCBI | |
Peralta S, Garcia S, Yin HY, Arguello T, Diaz F and Moraes CT: Sustained AMPK activation improves muscle function in a mitochondrial myopathy mouse model by promoting muscle fiber regeneration. Hum Mol Genet. 25:3178–3191. 2016. View Article : Google Scholar : PubMed/NCBI | |
Cotan D, Paz MV, Alcocer-Gomez E, Garrido-Maraver J, Oropesa-Ávila M, de la Mata M, Pavón AD, de Lavera I, Galán F, Ybot-González P and Sánchez-Alcázar JA: AMPK as a target in rare diseases. Curr Drug Targets. 17:921–931. 2016. View Article : Google Scholar : PubMed/NCBI | |
Li X, Liu R, Zhang L and Jiang Z: The emerging role of AMP-activated protein kinase in cholestatic liver diseases. Pharmacol Res. 125:105–113. 2017. View Article : Google Scholar : PubMed/NCBI | |
Woods A, Williams JR, Muckett PJ, Mayer FV, Liljevald M, Bohlooly-Y M and Carling D: Liver-specific activation of AMPK prevents steatosis on a high-fructose diet. Cell Rep. 18:3043–3051. 2017. View Article : Google Scholar : PubMed/NCBI | |
Liang Z, Li T, Jiang S, Xu J, Di W, Yang Z, Hu W and Yang Y: AMPK: A novel target for treating hepatic fibrosis. Oncotarget. 8:62780–62792. 2017.PubMed/NCBI | |
Yang C, Gong X, Ai Q, Ge P, Lin L and Zhang L: 5-Aminoimidazole-4-carboxamide-1-β-d-ribofuranoside alleviated carbon tetrachloride-induced acute hepatitis in mice. Int Immunopharmacol. 25:393–399. 2015. View Article : Google Scholar : PubMed/NCBI | |
Zhou D, Ai Q, Lin L, Gong X, Ge P, Che Q, Wan J, Wen A and Zhang L: 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside-attenuates LPS/D-Gal-induced acute hepatitis in mice. Innate Immun. 21:698–705. 2015. View Article : Google Scholar : PubMed/NCBI | |
Zhang M, Yang D, Gong X, Ge P, Dai J, Lin L and Zhang L: Protective benefits of AMP-activated protein kinase in hepatic ischemia-reperfusion injury. Am J Transl Res. 9:823–829. 2017.PubMed/NCBI | |
Jin J, Mullen TD, Hou Q, Bielawski J, Bielawska A, Zhang X, Obeid LM, Hannun YA and Hsu YT: AMPK inhibitor Compound C stimulates ceramide production and promotes Bax redistribution and apoptosis in MCF7 breast carcinoma cells. J Lipid Res. 50:2389–2397. 2009. View Article : Google Scholar : PubMed/NCBI | |
Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 108:1167–1174. 2001. View Article : Google Scholar : PubMed/NCBI | |
Yuan H, Li L, Zheng W, Wan J, Ge P, Li H and Zhang L: Antidiabetic drug metformin alleviates endotoxin-induced fulminant liver injury in mice. Int Immunopharmacol. 12:682–688. 2012. View Article : Google Scholar : PubMed/NCBI | |
Shackelford DB and Shaw RJ: The LKB1-AMPK pathway: Metabolism and growth control in tumour suppression. Nat Rev Cancer. 9:563–575. 2009. View Article : Google Scholar : PubMed/NCBI | |
Vazquez-Martin A, López-Bonet E, Oliveras-Ferraros C, Pérez-Martínez MC, Bernadó L and Menendez JA: Mitotic kinase dynamics of the active form of AMPK (phospho-AMPKalphaThr172) in human cancer cells. Cell Cycle. 8:788–791. 2009. View Article : Google Scholar : PubMed/NCBI | |
Vazquez-Martin A, Oliveras-Ferraros C, Cufi S and Menendez JA: Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus. Cell Cycle. 10:1295–1302. 2011. View Article : Google Scholar : PubMed/NCBI | |
Vazquez-Chantada M, Ariz U, Varela-Rey M, Embade N, Martínez-Lopez N, Fernández-Ramos D, Gómez-Santos L, Lamas S, Lu SC, Martínez-Chantar ML and Mato JM: Evidence for LKB1/AMP-activated protein kinase/endothelial nitric oxide synthase cascade regulated by hepatocyte growth factor, S-adenosylmethionine and nitric oxide in hepatocyte proliferation. Hepatology. 49:608–617. 2009. View Article : Google Scholar : PubMed/NCBI | |
Cai L, Hu K, Lin L, Ai Q, Ge P, Liu Y, Dai J, Ye B and Zhang L: AMPK dependent protective effects of metformin on tumor necrosis factor-induced apoptotic liver injury. Biochem Biophys Res Commun. 465:381–386. 2015. View Article : Google Scholar : PubMed/NCBI | |
Zhang T, Guo P, Zhang Y, Xiong H, Yu X, Xu S, Wang X, He D and Jin X: The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo. Int J Mol Sci. 14:24603–24618. 2013. View Article : Google Scholar : PubMed/NCBI | |
Qi H, Liu Y, Li S, Chen Y, Li L, Cao YE M, Shi P, Song C, Li B and Sun H: Activation of AMPK attenuated cardiac fibrosis by inhibiting CDK2 via p21/p27 and miR-29 family pathways in rats. Mol Ther Nucleic Acids. 8:277–290. 2017. View Article : Google Scholar : PubMed/NCBI | |
Liu PF, Hsu CJ, Tsai WL, Cheng JS, Chen JJ, Huang IF, Tseng HH, Chang HW and Shu CW: Ablation of ATG4B suppressed autophagy and activated AMPK for cell cycle arrest in cancer cells. Cell Physiol Biochem. 44:728–740. 2017. View Article : Google Scholar : PubMed/NCBI | |
Yang WL, Perillo W, Liou D, Marambaud P and Wang P: AMPK inhibitor compound C suppresses cell proliferation by induction of apoptosis and autophagy in human colorectal cancer cells. J Surg Oncol. 106:680–688. 2012. View Article : Google Scholar : PubMed/NCBI | |
Viswakarma N, Jia Y, Bai L, Gao Q, Lin B, Zhang X, Misra P, Rana A, Jain S, Gonzalez FJ, et al: The Med1 subunit of the mediator complex induces liver cell proliferation and is phosphorylated by AMP kinase. J Biol Chem. 288:27898–27911. 2013. View Article : Google Scholar : PubMed/NCBI | |
Vucicevic L, Misirkic M, Janjetovic K, Harhaji-Trajkovic L, Prica M, Stevanovic D, Isenovic E, Sudar E, Sumarac-Dumanovic M, Micic D and Trajkovic V: AMP-activated protein kinase-dependent and -independent mechanisms underlying in vitro antiglioma action of compound C. Biochem Pharmacol. 77:1684–1693. 2009. View Article : Google Scholar : PubMed/NCBI |